Humalog Basal KwikPen
Intermediate-acting insulin analogue (insulin lispro protamine) for blood glucose control in diabetes mellitus
Humalog Basal KwikPen contains insulin lispro protamine, an intermediate-acting insulin analogue used to manage blood glucose levels in people with type 1 and type 2 diabetes mellitus. Delivered via a convenient pre-filled pen device, it provides basal insulin coverage lasting approximately 12 to 15 hours. This medication requires a prescription and should be used as part of a comprehensive diabetes management plan under the guidance of a healthcare provider.
Quick Facts
Key Takeaways
- Humalog Basal KwikPen provides intermediate-acting basal insulin coverage for approximately 12 to 15 hours, helping to control blood glucose levels between meals and overnight.
- The most common side effect is hypoglycemia (low blood sugar). Always carry a fast-acting source of glucose and know the warning signs of low blood sugar.
- Do not mix Humalog Basal KwikPen with any other insulin in the pen. If basal-bolus therapy is prescribed, use separate injections for rapid-acting and intermediate-acting insulins.
- Rotate injection sites regularly (abdomen, thigh, upper arm) to reduce the risk of lipodystrophy, which can affect insulin absorption.
- Store unopened pens in the refrigerator (2-8 °C). Once in use, the pen can be kept at room temperature (below 30 °C) for up to 28 days.
What Is Humalog Basal KwikPen and What Is It Used For?
Humalog Basal KwikPen contains the active substance insulin lispro protamine, which is a modified form of human insulin produced by recombinant DNA technology using Escherichia coli bacteria. The protamine component slows the absorption of insulin lispro from the injection site, creating an intermediate-acting profile that provides steady background insulin over approximately 12 to 15 hours.
Insulin is a hormone naturally produced by the beta cells of the pancreas. It plays a central role in glucose metabolism by enabling cells throughout the body to absorb glucose from the bloodstream and use it as energy. In diabetes mellitus, the body either does not produce enough insulin (type 1 diabetes) or cannot use insulin effectively (type 2 diabetes), leading to elevated blood glucose levels (hyperglycemia). Chronic hyperglycemia is associated with serious long-term complications, including cardiovascular disease, nephropathy, retinopathy, and neuropathy.
As an intermediate-acting insulin, Humalog Basal KwikPen is designed to provide basal insulin coverage — the steady, low-level insulin that the body needs between meals and during sleep. This distinguishes it from rapid-acting insulin formulations (such as regular Humalog), which are taken before meals to handle post-meal blood glucose spikes. Many patients with diabetes use a combination of both basal and rapid-acting insulins, often referred to as basal-bolus therapy, to achieve optimal glycemic control.
The KwikPen delivery system is a disposable, pre-filled pen device designed for ease of use. It contains 3 mL of insulin lispro protamine suspension at a concentration of 100 IU/mL, delivering a total of 300 units per pen. The pen features a dose knob that allows patients to dial their prescribed dose in 1-unit increments, making it suitable for precise dose adjustments as directed by their healthcare provider.
Humalog Basal KwikPen is indicated for use in patients with type 1 diabetes mellitus (where insulin therapy is essential for survival) and type 2 diabetes mellitus (where other treatments, including oral medications and lifestyle interventions, have not achieved adequate glycemic control). It is approved for use in adults, adolescents, and children from the age of 2 years onwards, although dosing requirements vary significantly between patient populations and should always be individualized.
What Should You Know Before Taking Humalog Basal KwikPen?
Contraindications
Humalog Basal KwikPen must not be used in the following situations:
- Hypoglycemia: Never inject insulin when your blood glucose is already low. Using insulin during hypoglycemia can cause dangerously low blood sugar, which may lead to unconsciousness, seizures, or death.
- Allergy to insulin lispro: If you have had an allergic reaction to insulin lispro, protamine, or any of the excipients in the formulation, you must not use this product. Symptoms of severe allergy include rash over the whole body, difficulty breathing, rapid heartbeat, sweating, and a drop in blood pressure.
Warnings and Precautions
Before starting Humalog Basal KwikPen, discuss the following with your healthcare provider:
- Blood glucose monitoring: Regular self-monitoring of blood glucose (SMBG) is essential. Your healthcare provider will advise you on target ranges and how frequently to test. Continuous glucose monitoring (CGM) systems may also be recommended.
- Hypoglycemia awareness: Learn to recognize the early warning signs of low blood sugar, including sweating, trembling, rapid heartbeat, hunger, dizziness, and confusion. Some patients, particularly those with long-standing diabetes or those taking beta-blockers, may experience reduced hypoglycemia awareness.
- Liver and kidney disease: Impaired liver or kidney function can reduce the body's ability to metabolize and clear insulin, increasing the risk of hypoglycemia. Dose adjustments and more frequent monitoring may be necessary.
- Illness and stress: Physical or emotional stress, fever, infection, surgery, and trauma can increase insulin requirements. Blood glucose monitoring should be intensified during these periods.
- Injection site rotation: Consistently injecting in the same location can lead to lipodystrophy (changes in subcutaneous fat), which can impair insulin absorption. Rotate injection sites systematically within the same general area.
- Thiazolidinedione (TZD) combinations: Using insulin with thiazolidinediones (such as pioglitazone) may increase the risk of fluid retention and heart failure, especially in patients with pre-existing cardiac conditions.
- Driving and operating machinery: Hypoglycemia can impair concentration and reaction time. Check your blood glucose before driving and carry a fast-acting carbohydrate source.
Pregnancy and Breastfeeding
If you are pregnant, planning a pregnancy, or breastfeeding, consult your healthcare provider before using Humalog Basal KwikPen. Good glycemic control is particularly important during pregnancy, as both hyperglycemia and hypoglycemia can harm the developing fetus.
Insulin requirements often decrease during the first trimester and increase during the second and third trimesters. After delivery, insulin needs typically return rapidly to pre-pregnancy levels. Close monitoring and frequent dose adjustments are essential throughout pregnancy and the postpartum period.
Insulin lispro protamine is generally considered safe during breastfeeding, as insulin is not absorbed from the gastrointestinal tract in the nursing infant. However, women who are breastfeeding may require adjustments to their insulin dose and dietary intake. According to the American Diabetes Association (ADA) and the European Medicines Agency (EMA), insulin therapy can be continued during breastfeeding under medical supervision.
Always tell your healthcare provider about all other medications you are taking, including over-the-counter drugs, herbal products, and supplements. Several medications can affect blood glucose levels and may require adjustments to your insulin dose.
How Does Humalog Basal KwikPen Interact with Other Drugs?
Drug interactions with insulin are clinically significant because they can alter blood glucose control in unpredictable ways. Some medications enhance the glucose-lowering effect of insulin, increasing the risk of hypoglycemia, while others counteract insulin's effects, potentially leading to hyperglycemia. Understanding these interactions is critical for safe and effective diabetes management.
The following table summarizes the most important drug interactions with Humalog Basal KwikPen. This is not an exhaustive list, and patients should always inform their healthcare provider of all medications they are taking.
Major Interactions (Increased Hypoglycemia Risk)
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Sulfonylureas (glipizide, glyburide, glimepiride) | Stimulate pancreatic insulin secretion | High – Monitor blood glucose closely; dose reduction of one or both agents may be needed |
| ACE Inhibitors (lisinopril, enalapril, ramipril) | Increase insulin sensitivity | Moderate – May lower glucose unexpectedly, especially when starting therapy |
| MAO Inhibitors | Enhance insulin action via unclear mechanism | Moderate – Increased monitoring recommended |
| Beta-Blockers (propranolol, atenolol, metoprolol) | Mask hypoglycemia symptoms; may prolong hypoglycemic episodes | High – Can mask tachycardia; sweating remains as primary warning sign |
| Fibrates (fenofibrate, gemfibrozil) | Improve insulin sensitivity | Moderate – Monitor glucose when starting or stopping |
| Alcohol | Inhibits hepatic gluconeogenesis | High – Can cause severe, delayed hypoglycemia; avoid excessive consumption |
Medications That May Reduce Insulin Effectiveness
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Corticosteroids (prednisone, dexamethasone, hydrocortisone) | Increase hepatic glucose output and insulin resistance | High – May require significant insulin dose increases; especially with systemic use |
| Thiazide Diuretics (hydrochlorothiazide) | Reduce insulin sensitivity; impair insulin secretion via potassium depletion | Moderate – Monitor glucose and potassium levels |
| Thyroid Hormones (levothyroxine) | Increase glucose production and absorption | Moderate – Adjust insulin dose when thyroid function changes |
| Oral Contraceptives | Decrease insulin sensitivity | Low to Moderate – May require modest dose adjustments |
| Sympathomimetics (salbutamol, terbutaline, epinephrine) | Stimulate glycogenolysis and gluconeogenesis | Moderate – Transient effect; monitor glucose during acute use |
| Atypical Antipsychotics (olanzapine, clozapine, quetiapine) | Increase insulin resistance and weight gain | High – Can worsen glycemic control significantly |
Alcohol can cause severe and delayed hypoglycemia, sometimes occurring hours after drinking. This occurs because alcohol inhibits hepatic gluconeogenesis, the liver's ability to produce new glucose. If you choose to drink alcohol, do so in moderation with food, and monitor your blood glucose more frequently. Never consume alcohol on an empty stomach while taking insulin.
What Is the Correct Dosage of Humalog Basal KwikPen?
Insulin dosing is highly individualized and depends on multiple factors, including the type of diabetes, body weight, diet, physical activity level, concurrent medications, and overall glycemic targets. There is no single "standard" dose of Humalog Basal KwikPen. The following guidance reflects general principles from the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and product labeling. Always follow your healthcare provider's specific instructions.
Adults
Type 1 Diabetes
In type 1 diabetes, total daily insulin requirements typically range from 0.4 to 1.0 IU/kg/day. Approximately 40-50% of this total is usually provided as basal insulin (such as Humalog Basal KwikPen), with the remainder given as rapid-acting insulin at mealtimes. The basal dose is commonly split into one or two daily injections, often given at bedtime and/or in the morning.
Type 2 Diabetes
For patients with type 2 diabetes starting insulin therapy, a common approach is to begin with 0.1 to 0.2 IU/kg/day (or 10 units) of basal insulin, often given at bedtime or in the evening. The dose is then titrated upward by 2-4 units every 3-7 days based on fasting blood glucose readings, targeting a fasting glucose of 4.4 to 7.2 mmol/L (80 to 130 mg/dL) as per ADA guidelines.
Children (2 years and older)
Pediatric Dosing
Children with type 1 diabetes typically require 0.5 to 1.0 IU/kg/day of total insulin. During puberty, requirements may increase to 1.0 to 2.0 IU/kg/day due to hormonal changes that increase insulin resistance. Basal insulin usually comprises 40-50% of the total daily dose. Pediatric dosing must be carefully supervised by a specialist, and parents or caregivers should be thoroughly trained in insulin administration, blood glucose monitoring, and hypoglycemia management.
Elderly Patients
Geriatric Considerations
In elderly patients, insulin therapy should be initiated cautiously with lower starting doses. The risk of hypoglycemia is particularly concerning in older adults due to reduced hypoglycemia awareness, impaired counterregulatory responses, and the potential for falls and cardiovascular events. Glycemic targets may be relaxed (fasting glucose below 8.3 mmol/L or 150 mg/dL) in frail elderly patients, as recommended by the ADA/EASD consensus report. Kidney and liver function should be assessed regularly, as declining organ function may necessitate dose reductions.
Missed Dose
If you miss a dose of Humalog Basal KwikPen, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Never take a double dose to compensate for a missed one. Monitor your blood glucose more frequently after missing a dose and contact your healthcare provider if levels remain elevated.
Overdose
An overdose of insulin causes hypoglycemia, which can range from mild (treatable with oral glucose) to severe (requiring medical assistance). Symptoms include sweating, trembling, rapid heartbeat, confusion, blurred vision, difficulty speaking, and loss of consciousness. Mild hypoglycemia can be treated by consuming 15-20 grams of fast-acting carbohydrates (glucose tablets, fruit juice, or regular soda). Severe hypoglycemia, where the patient cannot self-treat, is a medical emergency requiring glucagon injection or intravenous glucose. Call your local emergency services immediately if someone with diabetes is unconscious or unable to swallow.
Humalog Basal KwikPen is administered by subcutaneous injection into the abdomen, thigh, or upper arm. The insulin suspension must appear uniformly cloudy or milky after resuspension. Before each injection, gently roll the pen between your palms 10 times and invert it 10 times. Do not use the pen if the insulin remains clear after resuspension, contains clumps, or appears frosted. Always use a new pen needle for each injection and never share your pen with another person, even if the needle is changed.
What Are the Side Effects of Humalog Basal KwikPen?
Like all medications, Humalog Basal KwikPen can cause side effects, although not everybody experiences them. The frequency classifications below are based on clinical trial data and post-marketing surveillance, following the Council for International Organizations of Medical Sciences (CIOMS) frequency categories used by the EMA and FDA.
The most important side effect to be aware of is hypoglycemia. Every patient using insulin should be educated about the signs, symptoms, and treatment of low blood sugar. Your healthcare team will work with you to minimize this risk through careful dose titration, blood glucose monitoring, and dietary planning.
Very Common (affects more than 1 in 10 people)
- Hypoglycemia – Low blood sugar causing sweating, trembling, rapid heartbeat, hunger, dizziness, confusion, blurred vision, and in severe cases, loss of consciousness or seizures
Common (affects 1 to 10 in 100 people)
- Injection site reactions – Redness, swelling, itching, or pain at the injection site; usually mild and transient
- Lipodystrophy – Thickening (lipohypertrophy) or thinning (lipoatrophy) of fat tissue at injection sites, which can affect insulin absorption
- Peripheral edema – Mild swelling of the hands, ankles, or feet, particularly at the start of insulin therapy or after intensification
- Weight gain – Insulin promotes glucose storage and can lead to modest weight gain over time
Uncommon (affects 1 to 10 in 1,000 people)
- Local allergic reactions – Rash, redness, or urticaria at or around the injection site
- Visual disturbances – Temporary changes in vision may occur when blood glucose control is rapidly improved, due to changes in lens refraction; this is usually transient
Rare (affects fewer than 1 in 1,000 people)
- Severe systemic allergic reactions (anaphylaxis) – Generalized rash, difficulty breathing, rapid heartbeat, sweating, drop in blood pressure; requires immediate medical attention
- Hypokalemia – Insulin shifts potassium into cells, potentially lowering blood potassium levels; risk is highest with high-dose insulin infusions
- Peripheral neuropathy – Rarely, rapid improvement in blood glucose control can be associated with painful neuropathy (insulin neuritis); this is usually temporary
Seek immediate medical attention if you experience any of the following: severe hypoglycemia with loss of consciousness or seizures; signs of a severe allergic reaction such as widespread rash, difficulty breathing, rapid heartbeat, or swelling of the face and throat; or sudden severe worsening of your condition. Call your local emergency number immediately.
If you experience any side effect not listed here, or if any side effect becomes severe, contact your healthcare provider. Reporting side effects helps regulatory authorities monitor the safety of medicines. In the EU, you can report side effects via the European Medicines Agency's national reporting system. In the US, contact the FDA's MedWatch program.
How Should You Store Humalog Basal KwikPen?
Proper storage of insulin is essential to maintain its effectiveness and safety. Insulin that has been improperly stored may lose potency without any visible change in appearance, potentially leading to poor glycemic control.
Unopened pens (not yet in use): Store in a refrigerator at 2 °C to 8 °C. Do not place the pen near the freezer compartment or cooling element. Never freeze insulin. Insulin that has been frozen must be discarded, as freezing destroys the insulin protein structure and renders it ineffective. Unopened pens stored correctly in the refrigerator can be used until the expiration date printed on the label and outer carton.
In-use pens (after first use): Once the pen has been used for the first time, it can be kept at room temperature below 30 °C for up to 28 days. Do not refrigerate a pen that is in use, as cold insulin injections can be more painful. After 28 days, discard the pen even if insulin remains in it. Write the date of first use on the pen to help track the 28-day window.
General storage precautions: Protect the pen from direct sunlight and heat. Do not leave the pen in a car, near a window in direct sunlight, or near a radiator. When traveling, use an insulated carrying case without ice packs directly touching the pen. Before each use, visually inspect the insulin. The suspension should appear uniformly cloudy or milky white after gentle resuspension. Do not use if it appears clear, contains visible particles or clumps, or looks frosted.
Disposal: Used pen needles and expired pens should be disposed of in an approved sharps container in accordance with local regulations. Do not dispose of needles in household waste. Many pharmacies and healthcare facilities offer sharps disposal services. Keep all insulin out of the reach and sight of children.
What Does Humalog Basal KwikPen Contain?
Understanding the complete composition of Humalog Basal KwikPen helps patients and healthcare providers identify potential allergens and understand the formulation's design. Each component serves a specific pharmaceutical purpose.
Active ingredient: Insulin lispro protamine – 100 IU per mL (equivalent to 3.5 mg per mL). This is a modified human insulin analogue produced by recombinant DNA technology in Escherichia coli. The protamine is added to form an insulin-protamine complex that slows absorption, providing intermediate-acting properties.
Inactive ingredients (excipients):
- Protamine sulfate – Forms a complex with insulin lispro to delay absorption and extend the duration of action
- Glycerol (glycerin) – Acts as an isotonic agent to make the formulation compatible with body fluids
- Dibasic sodium phosphate (sodium phosphate dibasic heptahydrate) – Serves as a pH buffer to maintain formulation stability
- Metacresol (m-cresol) – Antimicrobial preservative that maintains sterility after first use
- Phenol – Antimicrobial preservative used in combination with metacresol for effective multi-dose preservation
- Zinc oxide – Stabilizes the insulin hexamer structure, contributing to formulation stability and shelf life
- Water for injection – Pharmaceutical-grade water serving as the base solvent for the suspension
pH adjustment: Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH to approximately 7.0 to 7.8, ensuring physiological compatibility and patient comfort during injection.
The suspension has a white, cloudy appearance when properly resuspended. The KwikPen device itself is made from medical-grade plastic and contains a glass cartridge. Patients with known allergies to protamine (which can occur in individuals previously sensitized to protamine-containing products, including certain fish-derived protamine preparations) should inform their healthcare provider.
Frequently Asked Questions About Humalog Basal KwikPen
Medical References & Sources
All information in this article is based on peer-reviewed medical literature, international guidelines, and regulatory agency product information. The following sources were used:
- European Medicines Agency (EMA). Humalog – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Humalog Prescribing Information. Eli Lilly and Company. Last revised 2024. Available at: www.accessdata.fda.gov
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1). DOI: 10.2337/dc25-SINT
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. DOI: 10.2337/dci22-0034
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management (NG17). Last updated 2022.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Last updated 2022.
- British National Formulary (BNF). Insulin lispro. National Institute for Health and Care Excellence. 2025.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021.
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults: A Consensus Report by the ADA and EASD. Diabetes Care. 2021;44(11):2589-2625.
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed physicians and pharmacists specializing in endocrinology, diabetology, and clinical pharmacology. All content follows our strict editorial standards based on the GRADE evidence framework.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔍 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✏️ Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in endocrinology, diabetology, clinical pharmacology, and internal medicine.